*The following content is generated by AI and is for reference only.
Despropionyl Ramelteon Hydrochloride is a significant active metabolite of the pharmaceutical agent Ramelteon, a selective melatonin receptor agonist primarily utilized in the treatment of insomnia characterized by difficulty with sleep onset. While Ramelteon itself is marketed under brand names such as Rozerem, Despropionyl Ramelteon represents the primary circulating metabolite formed via hepatic metabolism, specifically through the cleavage of the propionyl group from the parent compound. This metabolic transformation is crucial for understanding the pharmacokinetic profile and therapeutic efficacy of the drug class.
The chemical identity of Despropionyl Ramelteon Hydrochloride distinguishes it by its specific molecular structure, which includes a hydrochloride salt form to enhance stability and solubility. Although exact molecular formulas and CAS numbers are often cataloged within specialized chemical databases like PubChem or DrugBank due to their status as metabolites rather than standalone commercial drugs, they generally reflect the de-esterified structure of the parent molecule combined with hydrochloric acid. In research contexts, this compound serves as an essential internal standard for bioanalytical assays, enabling scientists to quantify plasma concentrations of Ramelteon and its metabolites during clinical trials and pharmacokinetic studies. Its role extends beyond mere metabolic byproduct; it contributes to the overall duration of action and receptor binding dynamics within the suprachiasmatic nucleus, regulating circadian rhythms without causing significant sedation or dependency typical of traditional hypnotics.
Currently, Despropionyl Ramelteon Hydrochloride is not approved as a standalone therapeutic product for direct patient administration. Instead, it is predominantly utilized in the pharmaceutical industry for method development, quality control, and toxicological profiling. Researchers employ it to validate liquid chromatography-mass spectrometry (LC-MS) methods used to monitor drug levels in biological fluids. Furthermore, understanding its formation helps predict potential drug-drug interactions, particularly involving cytochrome P450 enzymes responsible for the oxidation and hydrolysis processes. As the demand for precise sleep disorder treatments grows, the study of such metabolites remains vital for optimizing dosing regimens and ensuring patient safety profiles remain favorable compared to older sedative-hypnotic classes.